


PHARMACEUTICAL 2019



DYNAVAX TECHNOLOGIES CORP Rank 260 of 371





PHARMACEUTICAL 2019



DYNAVAX TECHNOLOGIES CORP Rank 260 of 371

The relative strengths and weaknesses of DYNAVAX TECHNOLOGIES CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DYNAVAX TECHNOLOGIES CORP compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 35% points. The greatest weakness of DYNAVAX TECHNOLOGIES CORP is the variable Net Income, reducing the Economic Capital Ratio by 110% points.

The company's Economic Capital Ratio, given in the ranking table, is -322%, being 9.0% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	174,364
Cost of Goods Sold	0
Intangible Assets	13,861
Liabilities, Current	38,033
Liabilities, Non-Current	109,786
Other Assets	5,595
Other Compr. Net Income	-1,134
Other Expenses	31,134
Other Liabilities	0
Other Net Income	3,758
Property and Equipment	17,064
Research and Development	74,951
Revenues	8,198
Selling, General and Administrative Expense	64,770

Output Variable	Value in 1000 USD
Assets	210,884
Liabilities	147,819
Expenses	170,855
Stockholders Equity	63,065
Net Income	-158,899
Comprehensive Net Income	-159,466
Economic Capital Ratio	-322%